recombinant L-IFN adenovirus

Recombinant L-IFN adenovirus is an investigational gene therapy consisting of a replication-deficient adenoviral vector engineered to express the human interferon-lambda (L-IFN) gene. Developed by the First Affiliated Hospital of Fujian Medical University, this therapeutic candidate is primarily being evaluated for the treatment of recurrent glioblastoma. Upon administration, typically via intratumoral injection, the adenoviral vector delivers the L-IFN genetic sequence into target cells, resulting in the localized expression of interferon-lambda. As a Type III interferon, L-IFN exerts anti-tumor effects by activating signaling pathways that inhibit tumor cell proliferation, induce apoptosis, and enhance anti-tumor immunity. The use of L-IFN is hypothesized to offer a more favorable safety profile than Type I interferons due to the more restricted expression of its receptor (IFNLR1) on epithelial-derived cells and certain immune cells, potentially reducing systemic side effects.

Other names

recombinant L-interferon adenovirusadenovirus-mediated interferon-lambda gene therapy